Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECISE: Colchicine in TET2-CHIP Post-ACS Patients
NCT07362966Phase 4Recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of colchicine in Coronary atherosclerosis (CAD), sponsored by General Hospital of the Northern Theater Command. Started Jun 2026; status: recruiting.
02
Drugs
colchicine
03
Conditions
Coronary atherosclerosis (CAD)
Beyond the preview
Go deeper on NCT07362966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07362966.